SR One and Roche Venture Fund-backed Pandion Therapeutics will use the proceeds from the offering to advance a lead drug candidate for ulcerative colitis.
Pandion Therapeutics, a US-based autoimmune disease drug developer backed by conglomerate Access Industries and pharmaceutical firms Roche and GlaxoSmithKline (GSK), has filed for a $75m initial public offering.
Founded in 2016, Pandion is utilising protein engineering to develop treatments for autoimmune diseases. Part of the proceeds from the IPO will support phase 1a and phase 1b/2a clinical trials for its lead product candidate, PT101, which targets ulcerative colitis.
Additional capital will be used to advance two autoimmune disease candidates,…
